News & Stock

&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;lt;p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;gt;Your browser does not support iframes.&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;lt;/p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;gt;
&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;lt;p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;gt;Your browser does not support iframes.&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;lt;/p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;ampamp;gt;

About Valeant

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. Headquartered in Laval, Quebec, Valeant has more than 18,000 employees worldwide and is listed on both the New York Stock and Toronto Stock Exchanges under the symbol VRX.